Literature DB >> 15706356

Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.

Anton V Borovjagin1, Alexandre Krendelchtchikov, Nagarajan Ramesh, De-Chao Yu, Joanne T Douglas, David T Curiel.   

Abstract

The use of adenovirus type 5 (Ad5) for cancer therapy is limited by deficiency of its primary cell attachment receptor, coxsackie and adenovirus receptor (CAR), on cancer cells. Ad5 retargeting to alternate receptors through fiber genetic modification can be used to circumvent CAR dependence of its tropism, and thereby achieve infectivity enhancement. Here we propose and test a novel "complex mosaicism" approach for fiber modification, which combines serotype chimerism with peptide ligand(s) incorporation in a single-fiber molecule. We incorporated integrin-binding peptide RGD-4C in the HI-loop, at the carboxy (C)-terminus, or both locales of the Ad3 knob, in the context of Ad5/3 chimera fiber in order to retarget simultaneously the Ad vector to integrins and Ad3 receptors. The infectivity enhancement of the fiber modifications was assessed in various cancer cell lines as cancer-targeting models. Replication-defective complex mosaic Ad-luc vectors bearing chimeric fiber (F.5/3), with or without C-terminal RGD-modification of Ad3 knob, demonstrated up to 55-fold gene transfer increase in bladder cancer cell lines. Although this augmentation was primarily due to Ad3 receptor targeting, some contribution of RGD-mediated integrin-targeting was also observed, suggesting that complex mosaic modification can function in a dual-receptor targeting via a single Ad3 fiber knob.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706356     DOI: 10.1038/sj.cgt.7700806

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  18 in total

Review 1.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

2.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

Review 4.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  A genetic strategy for combined screening and localized imaging of breast cancer.

Authors:  Jason M Warram; Anton V Borovjagin; Kurt R Zinn
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

6.  Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.

Authors:  Sherry W Yang; James J Cody; Angel A Rivera; Reinhard Waehler; Minghui Wang; Kristopher J Kimball; Ronald A Alvarez; Gene P Siegal; Joanne T Douglas; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

7.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

8.  Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.

Authors:  M A Tyler; I V Ulasov; A M Sonabend; S Nandi; Y Han; S Marler; J Roth; M S Lesniak
Journal:  Gene Ther       Date:  2008-12-11       Impact factor: 5.250

9.  Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.

Authors:  Miho Murakami; Hideyo Ugai; Natalya Belousova; Alexander Pereboev; Paul Dent; Paul B Fisher; Maaike Everts; David T Curiel
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

10.  Enhancement of adenovirus delivery after ultrasound-stimulated therapy in a cancer model.

Authors:  Anna G Sorace; Jason M Warram; Marshall Mahoney; Kurt R Zinn; Kenneth Hoyt
Journal:  Ultrasound Med Biol       Date:  2013-09-21       Impact factor: 2.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.